Literature DB >> 18478012

Unraveling the mysteries of IGF-1 signaling in melanoma.

John T Lee1, Patricia Brafford, Meenhard Herlyn.   

Abstract

The inherent ability of a cell to undergo apoptosis governs a number of developmental processes essential to proper mammalian development. Into adulthood, the pathways that potentiate the apoptotic response are extremely diverse and finely regulated to prevent potential diseases. Of these, cancer is often associated with loss of an apoptotic response. Hanahan and Weinberg (2000) list evasion of apoptosis as a hallmark feature acquired during neoplastic transformation. The impact of this event is dramatic on several levels; avoidance of apoptosis not only prevents programmed cell death in an array of cell types but also promotes chemotherapeutic resistance during anticancer regimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18478012     DOI: 10.1038/jid.2008.124

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Response to "Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?".

Authors:  Yibing Ruan; Aru Narendran
Journal:  Neuro Oncol       Date:  2016-01       Impact factor: 12.300

Review 2.  Insulin-like growth factor system and sporadic malignant melanoma.

Authors:  Ettore Capoluongo
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

3.  Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt.

Authors:  Chen Chen Jiang; Fan Yang; Rick F Thorne; Bi Ke Zhu; Peter Hersey; Xu Dong Zhang
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

4.  Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways.

Authors:  Reetobrata Basu; Shiyong Wu; John J Kopchick
Journal:  Oncotarget       Date:  2017-03-28

5.  Iciartin, a novel FASN inhibitor, exerts anti-melanoma activities through IGF-1R/STAT3 signaling.

Authors:  Jinfeng Wu; Juan Du; Xiuqiong Fu; Bin Liu; Huihui Cao; Ting Li; Tao Su; Jinhua Xu; Anfernee Kai-Wing Tse; Zhi-Ling Yu
Journal:  Oncotarget       Date:  2016-08-09

6.  Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma.

Authors:  Reinhard Dummer; Olivier Michielin; Mirjam Chantal Nägeli; Simone M Goldinger; Federico Campigotto; Ulrike Kriemler-Krahn; Herbert Schmid; Alberto Pedroncelli; Sara Micaletto; Dirk Schadendorf
Journal:  ESMO Open       Date:  2018-07-23

7.  Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression.

Authors:  Berline Murekatete; Ali Shokoohmand; Jacqui McGovern; Lipsa Mohanty; Christoph Meinert; Brett G Hollier; Alfred Zippelius; Zee Upton; Abhishek S Kashyap
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.